Recent from talks
Deuruxolitinib
Knowledge base stats:
Talk channels stats:
Members stats:
Deuruxolitinib
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. It is a Janus kinase inhibitor selective for JAK1 and JAK2. Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.
Deuruxolitinib was approved for medical use in the United States in July 2024.
Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.
The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.
Deuruxolitinib was approved for medical use in the United States in July 2024.
Deuruxolitinib is the international nonproprietary name and the United States Adopted Name.
Hub AI
Deuruxolitinib AI simulator
(@Deuruxolitinib_simulator)
Deuruxolitinib
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. It is a Janus kinase inhibitor selective for JAK1 and JAK2. Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.
Deuruxolitinib was approved for medical use in the United States in July 2024.
Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.
The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.
Deuruxolitinib was approved for medical use in the United States in July 2024.
Deuruxolitinib is the international nonproprietary name and the United States Adopted Name.
Recent media